CuraGen, TopoTarget begin phase 1 trial of PXD101, cis-retinoic acid in solid tumors

By Lisa Kerner

Charlotte, N.C., June 14 - CuraGen Corp. and TopoTarget A/S began patient dosing in a National Cancer Institute-sponsored phase 1 clinical trial of PXD101, a small molecule histone deacetylase inhibitor, in combination with cis-retinoic acid for the treatment of patients with advanced solid tumors.

The open-label, dose-escalation study will establish the maximum tolerated dose and safety profile of PXD101, according to a company news release.

Up to 24 patients with advanced solid tumors will receive PXD101 and cis-retinoic acid in continuous three-week cycles until disease progression.

An additional 10 patients with tumors available for biopsy will be enrolled to complete planned molecular studies, the company said.

PXD101 is being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T-cell lymphoma, and colorectal and ovarian cancers, either alone or in combination with anticancer therapies.

CuraGen is a Branford, Conn., biopharmaceutical company developing novel protein, antibody and small molecule therapeutics for the treatment of cancer, inflammatory diseases and diabetes.

Denmark-based TopoTarget is a biopharmaceutical company specializing in cancer therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.